Drug intelligence / Profile preview

Alvocade

Development stage: Phase 4
Lead developer: NanoAlvand
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

Alvocade is a branded formulation of the proteasome inhibitor bortezomib, supplied as a lyophilized powder in vials for reconstitution and parenteral administration in oncology settings.[10] Bortezomib reversibly inhibits the 26S proteasome, disrupting targeted protein degradation, leading to accumulation of misfolded and regulatory proteins, induction of endoplasmic reticulum stress, and apoptosis, particularly in malignant plasma cells such as those in multiple myeloma and mantle cell lymphoma.[3] Alvocade is indicated for the treatment of multiple myeloma and mantle cell lymphoma and is developed and manufactured by Nanoalvand, a pharmaceutical company based in Iran.[10]

Brand names: Alvocade

Targets

PSMB6 (Proteasome 20S subunit beta 6)PSMB5 (Proteasome subunit beta Type-5)

Beyond the preview

Go deeper on Alvocade.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alvocade.

Explore the full profile